Literature DB >> 8419602

Effect of racemic epinephrine and salbutamol on clinical score and pulmonary mechanics in infants with bronchiolitis.

I Sanchez1, J De Koster, R E Powell, R Wolstein, V Chernick.   

Abstract

To test the efficacy of a combined alpha- and beta-receptor agonist in acute bronchiolitis, we compared inhaled racemic epinephrine with salbutamol in a double-blind, crossover, randomized protocol. Twenty-four infants, 4.6 +/- 0.5 (mean +/- SEM) months of age, with their first episode of bronchiolitis were tested. After sedation with chloral hydrate, a clinical score and pulmonary mechanics measurements using simultaneous signals of airflow volume and transpulmonary pressure were recorded. After baseline measurements, infants received either nebulized salbutamol, 0.03 ml/kg, or racemic epinephrine, 0.1 ml/kg. Thirty minutes later, there was a significant decrease in clinical score after treatment with racemic epinephrine compared with the baseline score (p < 0.001); this difference was not present after salbutamol inhalation (p = 0.42). Only 13 patients had a decrease in clinical score after salbutamol therapy, in comparison with 20 infants treated with racemic epinephrine (p < 0.01). Both drug decreased respiratory rate, but the decrease was greater after the use of racemic epinephrine (p < 0.001). There was a significant decrease in inspiratory, expiratory, and total pulmonary resistance after treatment with racemic epinephrine compared with baseline values (p < 0.01) but no significant change after salbutamol inhalation. There was no significant correlation between the clinical score and pulmonary mechanics either at baseline or after drug treatment. We conclude that racemic epinephrine is superior to salbutamol in the treatment of infants with their first episode of acute bronchiolitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419602     DOI: 10.1016/s0022-3476(05)83508-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Acute bronchiolitis--recent advances in treatment.

Authors:  G J Canny
Journal:  Indian J Pediatr       Date:  1996 Jan-Feb       Impact factor: 1.967

2.  Short term effects of adrenaline in bronchiolitis: a randomised controlled trial.

Authors:  A Abul-Ainine; D Luyt
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

3.  Role of steroids in croup and beta agonists in bronchiolitis.

Authors:  A Veerappan; A Kumar
Journal:  Indian J Pediatr       Date:  1996 Sep-Oct       Impact factor: 1.967

4.  Paediatric emergency research in Canada: Using the iterative loop of research as a paradigm for advancing the field.

Authors:  David W Johnson; Martin H Osmond; Nicola Hooton; Terry P Klassen
Journal:  Paediatr Child Health       Date:  2004-07       Impact factor: 2.253

Review 5.  Management of acute bronchiolitis.

Authors:  K Rakshi; J M Couriel
Journal:  Arch Dis Child       Date:  1994-11       Impact factor: 3.791

6.  Long-term management of asthma in First Nations and Inuit children: A knowledge translation tool based on Canadian paediatric asthma guidelines, intended for use by front-line health care professionals working in isolated communities.

Authors:  Tom Kovesi; Brenda Louise Giles; Hans Pasterkamp
Journal:  Paediatr Child Health       Date:  2012-08       Impact factor: 2.253

Review 7.  Bronchiolitis. Origins and optimal management.

Authors:  M L Everard
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 8.  Bronchodilators for bronchiolitis.

Authors:  Anne M Gadomski; Melissa B Scribani
Journal:  Cochrane Database Syst Rev       Date:  2014-06-17

9.  Comparision of Nebulised Salbutamol and L-epinephrine in First Time Wheezy Children.

Authors:  B M John; D Singh
Journal:  Med J Armed Forces India       Date:  2011-07-21

10.  Efficacy of Nebulised Epinephrine versus Salbutamol in Hospitalised Children with Bronchiolitis.

Authors:  B M John; S K Patnaik; P L Prasad
Journal:  Med J Armed Forces India       Date:  2011-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.